Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

913
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
913

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pregnancy, privacy, and procedural risk in dermatology.

Journal of the American Academy of Dermatology·2026
Same author

Alpelisib for TEK- and PIK3CA-Related Venous Malformations: A Systematic Review.

The Australasian journal of dermatology·2026
Same author

Autonomy vs nonmaleficence: Working out an isotretinoin dilemma.

Journal of the American Academy of Dermatology·2026
Same author

Infection Without Borders.

Journal of paediatrics and child health·2026
Same author

Effectiveness of a virtual hospital model of care for patients with low back pain presenting to emergency departments (Back@Home).

NPJ digital medicine·2026
Same author

Direct-to-consumer healthcare and its expanding role in the Australian healthcare system.

Internal medicine journal·2026

Related Experiment Video

Updated: May 29, 2025

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

10.3K

Biosimilars for Australian Dermatologists.

Grace X Li1,2, Mona Marabani3, Deshan F Sebaratnam1,2

  • 1South West Sydney Clinical School, University of New South Wales, Liverpool, New South Wales, Australia.

The Australasian Journal of Dermatology
|February 5, 2025
PubMed
Summary
This summary is machine-generated.

Biosimilars can significantly reduce Australian healthcare costs, especially in dermatology for chronic skin conditions. Overcoming barriers like clinician education and patient perception is key to their successful adoption and ensuring equitable access.

Keywords:
biologicbiological agentbiosimilardermatologyeconomicsustainability

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.8K
Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes
09:20

Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes

Published on: February 8, 2018

10.8K

Related Experiment Videos

Last Updated: May 29, 2025

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

10.3K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.8K
Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes
09:20

Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes

Published on: February 8, 2018

10.8K

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Dermatology

Background:

  • Biosimilars present a significant opportunity for cost reduction in the Australian healthcare system.
  • Biologics are crucial for managing chronic dermatological conditions, representing a substantial area for potential savings.
  • Patient and clinician factors, including education and perception, currently impede biosimilar uptake.

Purpose of the Study:

  • To evaluate the economic impact of biosimilars in Australia.
  • To identify barriers to biosimilar adoption in clinical practice.
  • To assess the role of biosimilars in the sustainability of the Pharmaceutical Benefits Scheme.

Main Methods:

  • Economic modeling to estimate cost savings.
  • Literature review on clinician and patient perceptions.
  • Analysis of current biosimilar uptake data.

Main Results:

  • Substantial cost savings are achievable through biosimilar use, particularly in long-term patient care for chronic skin diseases.
  • Key barriers to adoption include insufficient clinician education, concerns regarding safety and efficacy, and negative patient perceptions.
  • Increased biosimilar availability supports the Pharmaceutical Benefits Scheme and equitable healthcare access.

Conclusions:

  • Biosimilars offer significant economic benefits for the Australian healthcare system, especially in dermatology.
  • Addressing barriers related to education and perception is critical for maximizing biosimilar utilization.
  • Wider biosimilar adoption is essential for the long-term sustainability of pharmaceutical benefits and equitable healthcare access across Australia.